Emeline COLOMBA

Medical oncologist - Views my own.

[Yüksel Ürün @DrYukselUrun]

(Breast) Cancer care shouldn’t be a luxury.
We lose lives not just to cancer, but to lack of access, high costs, and trials that exclude too many.
Innovation must reach every patient, everywhere!
@Nature @curijoey @LoiSher @myESMO @ASCO @BreastCancerNow @tmprowell @uicc
https://t.co/yNVnGYb4LU

[Eric Topol @EricTopol]

The mechanisms by which ultra-processed foods (UPF) drive obesity, an outstanding review article
"the evidence is sufficiently strong to justify immediate public health efforts to reduce UPF consumption."
https://t.co/j03odD6ym0

[Emeline COLOMBA @EmelineColomba]

@dplanchard @alicebernardt @GustaveRoussy La fin d’une ère 😢

[Yüksel Ürün @DrYukselUrun]

🦠 The gut isn’t just digestion, it’s defense.
Microbiome = hidden player in cancer care.
➡️ Shapes immunity, response, toxicity, survival.
🧪 Fiber, FMT, even bacteria-based drugs are in the game now.
#Cancer #Immunotherapy #Microbiome #Oncology #GutHealth @JAMA_current @OncoAlert

doi:10.1001/jama.2025.2191

[Institut national du cancer @Institut_cancer]

🧵@Institut_cancer se félicite de l’adoption par l’@AssembleeNat de la proposition de loi portant création du registre national des cancers. Il en assurera le pilotage et la mise en œuvre. Cela représente un bond dans la surveillance épidémiologique des cancers sur le territoire.

[Emeline COLOMBA @EmelineColomba]

Congrats Mayuko!! So proud to have collaborated on this work which has such impact for PC patients from diversity! Contrats @MarlinRegine972 about adressing this question in FWI prostate cancer population!👏🏾👏🏾👏🏾

[Emmanuel Antonarakis @EAntonarakis]

A novel west-African germline founder mutation in HOXB13 (p.X285Kext) increases risk of high-grade prostate cancer but also enhances sensitivity to hormonal therapy. Congrats to PCF-funded Mayuko Kanayama 👏 @neerajaiims @PCFnews @urotoday @EdEsplin https://t.co/j2EzocJlys

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

https://t.co/JwWSPVqNvL

This phase I trial of pasritamig, a novel bispecific T-cell–engaging antibody targeting KLK2 in metastatic castration-resistant #prostateCancer , demonstrated a manageable safety profile with mostly low-grade adverse events and minimal cytokine release syndrome.

Showed promising preliminary antitumor activity, including a 42.4% PSA response rate and a median radiographic progression-free survival of 7.85 months, supporting further clinical development.

@drmnstein
@DebbieRobbrecht
@DogerStart
@MikeSchweizerMD
@EmilianoCalvo_
@meavdongen
@DrDariaGaut

Ping @OncoAlert 🚨
@Silke_Gillessen @AOmlin
@nataliagandur @bavilima

[Fabrice Barlesi @barlesi]

💬 Le parcours FRESH illustre pleinement notre engagement à étendre la médecine de précision pour tous les patients atteints de #cancer en France et à l’international, quels que soient leur lieu de vie et leur situation clinique.

⬇

[Stephen V Liu, MD @StephenVLiu]

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

[Emeline COLOMBA @EmelineColomba]

@DrChoueiri @GustaveRoussy @ASCO @ASCOPost @JCO_ASCO @CapuBaldini contrats !!! Good News for prostate cancer patients!

[Lizzy Smyth @LizzySmyth1]

#ASCO25

Many new drugs ➡️ welcome but marginal gains. 💰 Cost + ☣️ toxicity

Exercise ➡️ marginal cost + negligible toxicity

✅ Evidence based intervention should be added to standard treatment recommendations

No need to wait for regulatory approval! Do it now!

[Yüksel Ürün @DrYukselUrun]

Organ preservation dream becoming reality!
Neoadjuvant PD-1 blockade led to nonoperative management in 80% of early-stage dMMR solid tumors.
92% recurrence-free survival at 2 years.
Surgery was not needed: dignity, function, and hope preserved.
@NEJM @gonen_mithat @MSKCancerCenter @OncoAlert @AACR #AACR25
https://t.co/59XQy0wNqB

[Gustave Roussy @GustaveRoussy]

📰 « J’étais à mille lieues d’imaginer que j’avais un #cancer » : le difficile diagnostic de la maladie chez les adultes jeunes.

Retrouvez l'expertise de la Dr Cristina Smolenschi, via le projet Yoda, dans un article de @libe ⤵ https://t.co/6jZh4x1ry4

[Emeline COLOMBA @EmelineColomba]

Le congrès DICOM est fini @CHUM972 @ArsMartinique RV l’année prochaine le 27 et 28/2/26

[Emeline COLOMBA @EmelineColomba]

Brillante présentation du Pr Rouviere sur l’IA en radiologie dans le cancer de la prostate. @CHUM972 @CHUdeLyon

[Emeline COLOMBA @EmelineColomba]

L’accès au TEP PSMA @CHUM972 nous challenge :chez les patients positifs quel impact sur la stratégie thérapeutique ? 🤩Excellents topo du Pr Fizazi et @CalaisJeremie : un début de réponse 👏🏾

[Emeline COLOMBA @EmelineColomba]

@s_couraud Mais bientôt! Je t’envoie un save the date

[Emeline COLOMBA @EmelineColomba]

Première journée du congrès DICOM @CHUM972 @ArsMartinique : heureux de se retrouver pour échanger sur cancer de la prostate et imagerie

[Emeline COLOMBA @EmelineColomba]

Le dispositif d’appui en personnel de santé propose de consolider l’offre d’oncologie en outre-mer #UCOM ⁦@GRAlumni⁩ #unicancer https://t.co/RBDkbNCNNs

[Brandon Luu, MD @BrandonLuuMD]

Lifestyle is a stronger predictor of aging and mortality than genetics.

A new Nature study of ~500,000 people found:
🎯 17% of mortality variation was linked to lifestyle (exposome).
🧬 <2% of was explained by genetics.

Here’s what you need to know 👇🧵 1/10